林业发展局接受Teva提出的每月注射精神分裂症药物的申请。 FDA accepts Teva's application for monthly injectable schizophrenia drug.

美国食品和药物管理局接受了Teva的TEV -'749新药物申请,这是一种可长期释放注射的阿兰齐平剂,用于每月一次的成人精神分裂症治疗。 The U.S. FDA has accepted Teva's New Drug Application for TEV-'749, an extended-release injectable form of olanzapine, for once-monthly treatment of schizophrenia in adults. 接受是朝向可能批准迈出的关键一步,允许进一步审查药物的安全和功效。 The acceptance marks a key step toward potential approval, allowing further review of the drug's safety and efficacy. 如果获得批准,它将为管理精神分裂症的病人提供一个新的长效选择。 If approved, it would offer a new long-acting option for patients managing schizophrenia.